26 research outputs found
Undiagnosed mood disorders and sleep disturbances in primary care patients with chronic musculoskeletal pain.
Objective. The study aims to determine the prevalence
of undiagnosed comorbid mood disorders in
patients suffering chronic musculoskeletal pain in
a primary care setting and to identify sleep disturbances
and other associated factors in these
patients, and to compare the use of health services
by chronic musculoskeletal pain patients with and
without comorbid mood disorders.
Design. Cross-sectional study.
Subjects. A total of 1,006 patients with chronic musculoskeletal
pain from a representative sample of
primary care centers were evaluated.
Outcome Measures. Pain was measured using a
visual analog scale and the Primary Care Evaluation
of Mental Disorders questionnaire was used to
measure mood disorders.
Results. We observed a high prevalence of undiagnosed
mood disorders in chronic musculoskeletal
pain patients (74.7%, 95% confidence interval
[CI] 71.9–77.4%), with greater comorbidity in
women (adjusted odds ratio [OR] = 1.91, 95%
CI 1.37–2.66%) and widow(er)s (adjusted OR = 1.87,
95% CI 1.19–2.91%). Both sleep disturbances
(adjusted OR = 1.60, 95% CI 1.17–2.19%) and pain
intensity (adjusted OR = 1.02, 95% CI 1.01–1.02%)
displayed a direct relationship with mood disorders.
Moreover, we found that chronic musculoskeletal
pain patients with comorbid mood disorders availed
of health care services more frequently than those
without (P < 0.001).
Conclusions. The prevalence of undiagnosed mood
disorders in patients with chronic musculoskeletal
pain is very high in primary care settings. Our findings
suggest that greater attention should be paid to
this condition in general practice and that sleep disorders
should be evaluated in greater detail to
achieve accurate diagnoses and select the most
appropriate treatment
Pain exacerbates chronic mild stress-induced changes in noradrenergic transmission in rats
Depression can influence pain and vice versa, yet the biological mechanisms underlying how one influences the pathophysiology of the other remains unclear. Dysregulation of locus coeruleus-noradrenergic transmission is implicated in both conditions, although it is not known whether this effect is exacerbated in cases of co-morbid depression and chronic pain. We studied locus coeruleus activity using immunofluorescence and electrophysiological approaches in rats subjected to unpredictable chronic mild stress (CMS, an experimental model of depression) and/or chronic constriction injury (CCI, a model of chronic neuropathic pain) for 2 weeks. CCI alone had no effect on any of the locus coeruleus parameters studied, while CMS led to a slight reduction in the electrophysiological activity of the locus coeruleus. Furthermore, CMS was associated with an increase in the number of tyrosine hydroxylase-positive cells in the locus coeruleus, although they were smaller in size. Interestingly, these effects of CMS were exacerbated when combined with CCI, even though no changes in the α2-adrenoreceptors or the noradrenaline transporter were observed in any group. Together, these findings suggest that CMS triggers several modifications in locus coeruleus-noradrenergic transmission that are exacerbated by co-morbid chronic pain
Medically unexplained pain complaints are associated with underlying unrecognized mood disorders in primary care
<p>Abstract</p> <p>Background</p> <p>Patients with chronic pain frequently display comorbid depression, but the impact of this concurrence is often underestimated and mistreated. The aim of this study was to determine the prevalence of unrecognized major depression and other mood disorders and comorbid unexplained chronic pain in primary care settings and to explore the associated factors.</p> <p>Also, to compare the use of health services by patients with unexplained chronic pain, both with and without mood disorder comorbidity.</p> <p>Methods</p> <p>A cross-sectional study was carried out in a sample of primary care centers. 3189 patients consulting for "unexplained chronic pain" were assessed by the Visual Analogue Scales (VAS) and the Primary Care Evaluation of Mental Disorders (PRIME-MD) questionnaire.</p> <p>Results</p> <p>We report: a) a high prevalence of unrecognized mood disorders in patients suffering from unexplained chronic pain complaints (80.4%: CI 95%: 79.0%; 81.8%); b) a greater susceptibility of women to mood disorders (OR adjusted = 1.48; CI 95%:1.22; 1.81); c) a direct relationship between the prevalence of mood disorders and the duration of pain (OR adjusted = 1.01; CI 95%: 1.01; 1.02) d) a higher comorbidity with depression if the pain etiology was unknown (OR adjusted = 1.74; CI 95%: 1.45; 2.10) and, e) an increased use of health care services in patients with such a comorbidity (p < 0.0001).</p> <p>Conclusions</p> <p>The prevalence of undiagnosed mood disorders in patients with unexplained chronic pain in primary care is very high, leading to dissatisfaction with treatment processes and poorer outcomes. Consequently, it seems necessary to explore this condition more regularly in general practice in order to reach accurate diagnoses and to select the appropriate treatment.</p
Effect of tapentadol on neurons in the locus coeruleus
Tapentadol is a novel centrally acting drug that combines mu-opioid receptor (MOR) agonism and
noradrenaline reuptake inhibition (NRI), producing analgesic effects in various painful conditions. We
investigated the acute effects of tapentadol in the locus coeruleus (LC), a central nucleus regulated by the
noradrenergic and opioid systems that is critical in pain modulation. In single-unit extracellular recordings
of LC neurons from anaesthetized male SpragueeDawley rats, tapentadol clearly inhibited the
spontaneous electrophysiological activity of LC neurons in a dose-dependent manner (ED50 ÂĽ 0.8 mg/kg).
This inhibitory effect was reversed by RX821002 (an alpha2-adrenoceptor antagonist) and naloxone (a
mu-opioid receptor antagonist) by 96.7% and 28.2%, respectively. Pretreatment with RX821002, Nethoxycarbonyl-
2-ethoxy-1-2-dihydroquinoline (EEDQ, an irreversible alpha2-adrenoceptor antagonist)
or naloxone shifted the tapentadol doseeeffect curve to the right (ED50 ÂĽ 2.2 mg/kg, 2.0 mg/kg and
2.1 mg/kg, respectively). Furthermore, tapentadol inhibited the LC response to mechanical stimulation of
the hindpaw in a dose-dependent manner. In summary, we demonstrate that acute administration of
tapentadol inhibits LC neurons in vivo, mainly due to the activation of alpha2-adrenoceptors. These data
suggest that both the noradrenergic and opioid systems participate in the inhibitory effect of tapentadol
on LC neurons, albeit to different extents, which may account for its potent analgesic effect and mild
opioidergic side-effects.This study was supported by grants from GrĂĽnenthal GmbH
(OT2010/075); “Fondo de Investigación Sanitaria” (PI10/01221 and
PI12/00915); CIBERSAM (G18); Junta de AndalucĂa, ConsejerĂa de
InnovaciĂłn, Ciencia y Empresa (CTS-510, CTS-4303 and CTS-7748);
Cátedra Externa del Dolor Grünenthal-Universidad de Cádiz;
FP7-PEOPLE-2010-RG (268377); FPU (AP2007-02397) and FPI
(2011-145) fellowship
Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain
International audienceTapentadol is an analgesic that acts as an agonist of µ opioid receptors (MOR) and that inhibits noradrenaline reuptake. Data from healthy rats show that tapentadol inhibits neuronal activity in the locus coeruleus (LC), a nucleus regulated by both the noradrenergic and opioid systems. Thus, we set out to investigate the effect of tapentadol on LC activity in streptozotocin (STZ)-induced diabetic rats, a model of diabetic polyneuropathy, by analyzing single-unit extracellular recordings of LC neurons. Four weeks after inducing diabetes, tapentadol dose-response curves were obtained from animals pre-treated with RX821002 or naloxone (alpha2-adrenoceptors and opioid receptors antagonists, respectively). In STZ rats, the spontaneous activity of LC neurons (0.9 ± 0.1 Hz) was lower than in naïve animals (1.5 ± 0.1 Hz), and tapentadol's inhibitory effect was also weaker. Alpha2-adrenoceptors blockade by RX821002 (100 μg/kg i.v.) in STZ animals significantly increased the spontaneous activity (from 0.8 ± 0.1 to 1.4 ± 0.2 Hz) and it dampened the inhibition of LC neurons produced by tapentadol. However, opioid receptors blockade following naloxone pre-treatment (5 mg/kg i.v.) did not alter the spontaneous firing rate (0.9 ± 0.2 vs 0.9 ± 0.2 Hz) or the inhibitory effect of tapentadol on LC neurons in STZ animals. Thus, diabetic polyneuropathy appears to exert neuroplastic changes in LC neurotransmission, enhancing the sensitivity of alpha2-adrenoceptors and dampening opioid receptors expression. Tapentadol's activity seems to be predominantly mediated through its noradrenergic effects rather than its influence on opioid receptors in the STZ model of diabetic polyneuropathy
Factors associated with chronic pain in patients with bipolar depression: a cross-sectional study
Background: While pain is frequently associated with unipolar depression, few studies have investigated the link between pain and bipolar depression. In the present study we estimated the prevalence and characteristics of pain among patients with bipolar depression treated by psychiatrists in their regular clinical practice. The study was designed to identify factors associated with the manifestation of pain in these patients.-
Methods:Patients diagnosed with bipolar disorder (n=121) were selected to participate in a cross-sectional study in which DSM-IV-TR criteria were employed to identify depressive episodes. The patients were asked to describe any pain experienced during the study, and in the 6 weeks beforehand, by means of a Visual Analogical Scale (VAS).-
Results: Over half of the bipolar depressed patients (51.2%, 95% CI: 41.9%–60.6%), and 2/3 of the female experienced concomitant pain. The pain was of moderate to severe intensity and prolonged duration, and it occurred at multiple sites, significantly limiting the patient’s everyday activities. The most important factors associated with the presence of pain were older age, sleep disorders and delayed diagnosis of bipolar disorder.-
Conclusions: Chronic pain is common in bipolar depressed patients, and it is related to sleep disorders and delayed diagnosis of their disorder. More attention should be paid to study the presence of pain in bipolar depressed patients, in order to achieve more accurate diagnoses and to provide better treatment options.This work was partially supported by KRONIK 11/010
Prevalence of central and peripheral neuropathic pain in patients attending pain clinics in Spain: factors related to intensity of pain and quality of life.
The objective of the study was to estimate the prevalence of pure central neuropathic pain (CNP) and peripheral neuropathic pain (PNP) among patients attending pain clinics in Spain. The study also aimed to analyze factors associated with pain intensity and quality of life (QoL). A cross-sectional study was performed including 53 patients with pure CNP and 281 with pure PNP attending in 104 pain clinics in Spain. The revised grading system proposed in 2008 to determine a definite, probable or possible diagnosis of NP was used. Pain features, psychological variables and QoL were assessed. Descriptive, bivariate and multivariate analyses were performed. The prevalence of pure CNP and PNP amongst neuropathic pain patients was 2.4% (95% CI: 1.7;3.1) and 12.9% (95% CI: 1.5;14.3), respectively. Comorbid anxiety, depression or sleep disorders were high in both groups, but higher in CNP patients (51.1%, 71.4%, respectively). Pain intensity in PNP patients was associated with the presence of depression and sleep disturbances. However, in CNP patients, it was related with pain in the lower limbs. The impairment of QoL was greater in CNP patients than in PNP patients; pain location, presence of depression and sleep disturbance were the factors that most negatively affected QoL. Among PNP patients, women and those with higher pain intensity had worse QoL. Pain intensity and QoL are affected by different factors in patients suffering from CNP or PNP. Identifying these factors could serve to guide therapeutic strategies and improve the QoL of patients
Role of serotonin 5-HT1A receptors in the antidepressant-like effect and the antinociceptive effect of venlafaxine in mice
On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
Altres ajuts: Acord transformatiu CRUE-CSICBackground. Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established.Aims to evaluate the impact of HBsAg kinetics before treatment interruption on post-treatment response. Methods. Longitudinal, ambispective study in non-cirrhotic chronic hepatitis B HBeAg-negative patients, analysing on-treatment and post-treatment HBsAg kinetics. On-treatment HBsAg kinetics diagnostic accuracy (AUROC) to identify HBsAg loss was evaluated. Results. 52 HBeAg-negative patients stopped treatment after 8.2 years, and 6 (11.5%) achieved HBsAg loss one year after withdrawal. Multivariate analysis showed that on-treatment HBsAg kinetics was related to HBsAg loss (OR=0.10; 95%CI=0.016-0.632; p = 0.014) with a high diagnostic accuracy (AUROC=0.935). A significant HBsAg decline ≥1 log10 IU/mL showed a positive and negative predictive value of 50% and of 97.6%, respectively. After treatment interruption, HBsAg decline speed (log10 IU/mL/year) accelerated in patients treated >6 years (from -0.06 to -0.20, p<0.05) and remained stable in treated <6 years (from -0.12 to -0.12 p=ns). Conclusions. On-treatment HBsAg kinetics can predict post-treatment HBsAg loss rate. Half of patients with a significant HBsAg decline can eliminate HBsAg the first year after withdrawal. Post-treatment HBsAg decline is faster not only in patients who lost the HBsAg but also in those who remain HBsAg-positive. HBsAghepatitis B surface antigenHBeAghepatitis B e antigenNAnucleos(t)ides analoguesHBVhepatitis B virusORodds ratioCIconfidence intervalCHBchronic hepatitis BETVentecavirTDFtenofovir disoproxil fumarateEoTend of treatmentTEtransient elastographyVRvirological relapseCRclinical relapseALTalanine aminotransferaseULNupper limit of normalityILinterleukinIQRinterquartile rangePeg-IFNpegylated interferonAUROCarea under receiver operating characteristicSsensitivitySpspecificityPPVpositive predictive valueNPVnegative predictive value+LRpositive likelihood ratio-LRnegative likelihood ratio